Literature DB >> 7936113

Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies.

J E De Séréville1, C Boer, F A Rambert, J Duteil.   

Abstract

Modafinil was compared to the indirect dopaminergic drugs, dexamphetamine and methylphenidate, using in vivo differential normal pulse voltammetry with carbon fibre electrodes located in the caudate nucleus to study extracellular catechol level in anaesthetized mice. Modafinil (16-256 mg kg-1) failed to modify the catechol oxidation peak height (peak 2). Dexamphetamine at low doses (2 and 4 mg kg-1) decreased, while at a higher dose (8 mg kg-1) did not modify peak 2 height. A low dose of methylphenidate (16 mg kg-1) did not display any effect, while higher doses (32 and 64 mg kg-1) increased peak 2 height. Pargyline-induced monoamine oxidase inhibition elicited a rapid and dramatic decrease in peak 2 height (related to the decrease of catechol levels). In these conditions modafinil (64 and 256 mg kg-1) did not modify, while dexamphetamine (2, 4 and 8 mg kg-1) and methylphenidate (16, 32 and 64 mg kg-1) increased peak 2 height in relation to synaptic dopamine level increase. This study, in mice, demonstrated the lack of effects of modafinil on nigro-striatal function, at the pre-synaptic level, as opposed to dexamphetamine and methylphenidate.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936113     DOI: 10.1016/0028-3908(94)90115-5

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  10 in total

1.  Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission.

Authors:  C Sebban; X Q Zhang; B Tesolin-Decros; M J Millan; M Spedding
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Non-cholinergic modulation of antisaccade performance: a modafinil-nicotine comparison.

Authors:  N Rycroft; S B Hutton; O Clowry; C Groomsbridge; A Sierakowski; J M Rusted
Journal:  Psychopharmacology (Berl)       Date:  2007-08-05       Impact factor: 4.530

Review 3.  Modafinil : a review of its use in excessive sleepiness associated with obstructive sleep apnoea/hypopnoea syndrome and shift work sleep disorder.

Authors:  Gillian M Keating; Michael J Raffin
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Modafinil : A Review of its Pharmacology and Clinical Efficacy in the Management of Narcolepsy.

Authors:  K J McClellan; C M Spencer
Journal:  CNS Drugs       Date:  1998-04       Impact factor: 5.749

Review 5.  Clinical pharmacokinetic profile of modafinil.

Authors:  Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

6.  A retrospective review of supratherapeutic modafinil exposures.

Authors:  Shaun D Carstairs; Andrew Urquhart; Justin Hoffman; Richard F Clark; F Lee Cantrell
Journal:  J Med Toxicol       Date:  2010-09

Review 7.  Approved and investigational uses of modafinil : an evidence-based review.

Authors:  Raminder Kumar
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Open-label pilot study of modafinil for methamphetamine dependence.

Authors:  Janette McGaugh; Michael J Mancino; Zachary Feldman; Mohit P Chopra; W Brooks Gentry; Christopher Cargile; Alison Oliveto
Journal:  J Clin Psychopharmacol       Date:  2009-10       Impact factor: 3.153

9.  A review of modafinil film-coated tablets for attention-deficit/hyperactivity disorder in children and adolescents.

Authors:  Thomas Rugino
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

10.  Neurophysiology of sleep and wakefulness: basic science and clinical implications.

Authors:  Jonathan R L Schwartz; Thomas Roth
Journal:  Curr Neuropharmacol       Date:  2008-12       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.